Dr. Patil Tejas, MD

Claim this profile
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
1 reported clinical trial
1 drug studied

Area of expertise

1Lung Cancer
Patil Tejas, MD has run 1 trial for Lung Cancer. Some of their research focus areas include:
Stage III
RET positive
Stage IV
2Non-Small Cell Lung Cancer
Patil Tejas, MD has run 1 trial for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Stage III
RET positive
Stage IV

Clinical Trials Patil Tejas, MD is currently running

More about Patil Tejas, MD

Clinical Trial Related1 year of experience running clinical trials · Led 1 trial as a Principal Investigator · 1 Active Clinical Trial
Treatments Patil Tejas, MD has experience with
  • Amivantamab
Breakdown of trials Patil Tejas, MD has run
Non-Small Cell Lung Cancer

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Patil Tejas, MD specialize in?
Patil Tejas, MD focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage III patients, or patients who are RET positive.
Is Patil Tejas, MD currently recruiting for clinical trials?
Yes, Patil Tejas, MD is currently recruiting for 1 clinical trial in the USA. If you're interested in participating, you should apply.
Are there any treatments that Patil Tejas, MD has studied deeply?
Yes, Patil Tejas, MD has studied treatments such as Amivantamab.
What is the best way to schedule an appointment with Patil Tejas, MD?
Apply for one of the trials that Patil Tejas, MD is conducting.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.